Product Description
SCO-240, identified by SCOHIA researchers and collaborators, is an orally available, selective SSTR5 antagonist and is unique owing to its dual action of increasing hormone secretions and insulin sensitivity. SSTR5 antagonism effectively stimulates insulin and GLP-1 secretion, increases insulin sensitivity, and improves glycemic control in preclinical diabetes models. Considering its dual action, SCO-240 may be a novel alternative for the treatment of diabetes. (Sourced from: https://www.scohia.com/eng/sys/pipeline/sco-240/)
Mechanisms of Action: SSTR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: SCOHIA PHARMA, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Cholelithiasis|Hypopituitarism
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2051210027 |
jRCT2051210027 | P1 |
Not yet recruiting |
Cholelithiasis |
2021-10-30 |
|||
jRCT2051240252 |
jRCT2051240252 | P1 |
Recruiting |
Hypopituitarism |
2025-05-31 |
Recent News Events
Date |
Type |
Title |
|---|